ME01952B - 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones - Google Patents

2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones

Info

Publication number
ME01952B
ME01952B MEP-2011-334A MEP33411A ME01952B ME 01952 B ME01952 B ME 01952B ME P33411 A MEP33411 A ME P33411A ME 01952 B ME01952 B ME 01952B
Authority
ME
Montenegro
Prior art keywords
amino
pyrimidin
phenyl
methyl
fluoro
Prior art date
Application number
MEP-2011-334A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
X Michael Wang
Kris Mendenhall
Yasheen Zhou
Baoqing Gong
Dan Gu
John Dolan
John Tulinsky
Kristin Brinner
Zhenhai Gao
Daniel Poon
Timothy D Machajewski
Paul A Barsanti
Xiaodong Lin
Abran Costales
Alice Rico
Nathan Brammeier
Teresa Pick
Paul A Renhowe
Cynthia M Shafer
Christopher Mcbride
William Antonios-Mccrea
Brandon M Doughan
Barry H Levine
Yi Xia
Maureen Mckenna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ME01952B publication Critical patent/ME01952B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
MEP-2011-334A 2005-09-30 2006-09-28 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones ME01952B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72279605P 2005-09-30 2005-09-30
US83688606P 2006-08-09 2006-08-09
PCT/US2006/038181 WO2007041362A1 (en) 2005-09-30 2006-09-28 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
EP06825272A EP1928875B1 (en) 2005-09-30 2006-09-28 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
ME01952B true ME01952B (en) 2011-12-31

Family

ID=37661234

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2011-334A ME01952B (en) 2005-09-30 2006-09-28 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones

Country Status (31)

Country Link
US (2) US7671059B2 (enExample)
EP (1) EP1928875B1 (enExample)
JP (2) JP5036002B2 (enExample)
KR (1) KR101311757B1 (enExample)
AR (1) AR058072A1 (enExample)
AT (1) ATE514694T1 (enExample)
AU (1) AU2006297124B2 (enExample)
BR (1) BRPI0616701A2 (enExample)
CA (1) CA2624253C (enExample)
CR (1) CR9846A (enExample)
CY (1) CY1112028T1 (enExample)
DK (1) DK1928875T3 (enExample)
EA (1) EA016152B1 (enExample)
EC (1) ECSP088324A (enExample)
GE (1) GEP20115231B (enExample)
HR (1) HRP20110655T1 (enExample)
IL (1) IL190446A0 (enExample)
JO (1) JO2783B1 (enExample)
MA (1) MA29885B1 (enExample)
ME (1) ME01952B (enExample)
MY (1) MY143604A (enExample)
NO (1) NO342258B1 (enExample)
NZ (1) NZ566914A (enExample)
PE (1) PE20070621A1 (enExample)
PL (1) PL1928875T3 (enExample)
PT (1) PT1928875E (enExample)
RS (1) RS51795B (enExample)
SM (1) SMAP200800029A (enExample)
TN (1) TNSN08143A1 (enExample)
TW (1) TWI373471B (enExample)
WO (1) WO2007041362A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101225083A (zh) * 2007-01-16 2008-07-23 北京摩力克科技有限公司 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
BRPI0906598A2 (pt) * 2008-02-01 2015-07-07 Takeda Pharmaceutical Oxim derivattivos como inibidores hsp90
WO2010034670A2 (en) * 2008-09-26 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
MA32933B1 (fr) * 2008-11-28 2012-01-02 Novartis Ag Combinaison d'inhibiteurs de hspo90 et d'herceptine
US20110230499A1 (en) * 2008-11-28 2011-09-22 Novartis Ag Hsp90 inhibitors for therapeutic treatment
PT2370076T (pt) * 2008-11-28 2017-03-31 Novartis Ag Combinações de inibidor hsp90
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011053861A1 (en) 2009-10-29 2011-05-05 Genosco Kinase inhibitors
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
KR20140078656A (ko) 2011-10-14 2014-06-25 노파르티스 아게 증식성 질환의 치료를 위한 hsp90 억제제와 조합된 2-카르복스아미드 시클로아미노 우레아 유도체
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
CN103664938A (zh) * 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 含有嘧啶并环的syk抑制剂
AU2013341271A1 (en) 2012-11-07 2015-05-14 Novartis Ag Combination therapy
US9677907B2 (en) * 2013-03-14 2017-06-13 Itron Inc Intelligent receptacle
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
PL3053578T3 (pl) * 2013-09-30 2021-06-14 Taiho Pharmaceutical Co., Ltd. Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego
CN106795154B (zh) * 2014-09-02 2019-07-05 皮埃尔法布雷医药公司 用于治疗癌症的异喹啉酮衍生物
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
KR101653560B1 (ko) * 2016-02-02 2016-09-12 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
RU2629599C1 (ru) * 2016-09-28 2017-08-30 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ химиолучевого лечения опухолей прямой кишки и анального канала
US11542299B2 (en) 2017-06-09 2023-01-03 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptide containing N-substituted amino acid
US20230295108A1 (en) * 2020-06-26 2023-09-21 Nihon Nohyaku Co., Ltd. Aryltetrahydropyridine derivative or salt thereof, insecticidal agent containing the compound, and method of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6165873A (ja) * 1984-09-07 1986-04-04 Mitsui Petrochem Ind Ltd 2−ピペラジノピリミジン誘導体
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
IL85347A0 (en) * 1987-02-11 1988-07-31 May & Baker Ltd Cyclic diones
ATE305303T1 (de) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2006074293A2 (en) * 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
JP2008536867A (ja) * 2005-04-14 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 増殖疾患を処置する際に有用なhsp90インヒビターとしての2−アミノ−キナゾリン−5−オン

Also Published As

Publication number Publication date
IL190446A0 (en) 2008-11-03
KR20080057318A (ko) 2008-06-24
US20070123546A1 (en) 2007-05-31
TNSN08143A1 (en) 2009-07-14
US7671059B2 (en) 2010-03-02
HK1118823A1 (en) 2009-02-20
CA2624253A1 (en) 2007-04-12
MY143604A (en) 2011-06-15
JP2009510108A (ja) 2009-03-12
GEP20115231B (en) 2011-06-10
JP5036002B2 (ja) 2012-09-26
NZ566914A (en) 2011-09-30
PL1928875T3 (pl) 2011-11-30
HRP20110655T1 (hr) 2011-10-31
AU2006297124B2 (en) 2011-12-08
CA2624253C (en) 2015-06-16
SMP200800029B (it) 2008-05-07
KR101311757B1 (ko) 2013-09-26
WO2007041362A1 (en) 2007-04-12
MA29885B1 (fr) 2008-10-03
US20100004237A1 (en) 2010-01-07
ECSP088324A (es) 2008-04-28
BRPI0616701A2 (pt) 2011-06-28
TWI373471B (en) 2012-10-01
EA016152B1 (ru) 2012-02-28
DK1928875T3 (da) 2011-10-03
CY1112028T1 (el) 2015-11-04
EP1928875B1 (en) 2011-06-29
NO20082069L (no) 2008-06-09
EA200800992A1 (ru) 2008-10-30
JO2783B1 (en) 2014-03-15
PE20070621A1 (es) 2007-09-06
SMAP200800029A (it) 2008-05-07
NO342258B1 (no) 2018-04-30
JP2012158611A (ja) 2012-08-23
TW200728304A (en) 2007-08-01
EP1928875A1 (en) 2008-06-11
RS51795B (sr) 2011-12-31
PT1928875E (pt) 2011-09-06
AU2006297124A1 (en) 2007-04-12
ATE514694T1 (de) 2011-07-15
AR058072A1 (es) 2008-01-23
CR9846A (es) 2008-08-01

Similar Documents

Publication Publication Date Title
ME01952B (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
ES2916220T3 (es) Inhibidores del receptor de factor de crecimiento de fibroblasto
JP2009510108A5 (enExample)
AU2019340767B9 (en) Triazolo-pyrimidine compounds and uses thereof
TWI629266B (zh) 纖維母細胞生長因子受體之抑制劑
Lenz et al. TAS-102, a novel antitumor agent: a review of the mechanism of action
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
CN104755478A (zh) 丝氨酸/苏氨酸激酶抑制剂
CN104844580B (zh) 嘧啶类化合物、其制备方法及医药用途
JP2016522232A5 (enExample)
CN107250130B (zh) 杂环化合物及包含其的药物组合物
KR20150104089A (ko) 치환된 인돌-5-올 유도체와 그들의 치료적 용도
JP2008536867A5 (enExample)
CN106117185B (zh) 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
KR20150014476A (ko) 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
JP2016522231A5 (enExample)
JP2016514717A5 (enExample)
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
JP2006508981A5 (enExample)
RU2017140446A (ru) Гетероарильное производное или его фармацевтически приемлемая соль, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с pi3 киназами, содержащая данное действующее вещество
JP2018501209A5 (enExample)
RU2007142007A (ru) 2-аминохиназолин-5-оны
CN102227220A (zh) 用于治疗性治疗的Hsp90抑制剂
CA2568725A1 (en) Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
JP2010525047A (ja) 増殖状態の処置のためのEphB4キナーゼ阻害剤としてのN’−(フェニル)−N−(モルホリン−4−イル−ピリジン−2−イル)−ピリミジン−2,4−ジアミン誘導体